menu
    • menu
    [{"orgOrder":0,"company":"GluBio Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Protein","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GluBio Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"GluBio Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"GluBio Therapeutics \/ Qiming Venture Partners"}]

    Find Clinical Drug Pipeline Developments & Deals by GluBio Therapeutics

    Menu

    GluBio Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GluBio Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            GluBio Therapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Qiming Venture Partners

                            Deal Size : $22.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            GluBio Completes Series A+ Financing of $22 Million to Advance the Development of Novel TPD Drugs

                            Details : The investment will help advance two molecular glue protein degraders with best-in-class potential into the clinic for hematological malignancies, accelerate the lead optimization entry of three first-in-class TPD drugs for solid tumors and inflammatory ...

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 01, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Qiming Venture Partners

                            Deal Size : $22.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth